When was BioNTech founded?

BioNTech was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is BioNTech located?

BioNTech is headquartered in Mainz, Germany.

How many employees does BioNTech have?

As of May 31, 2026, the latest employee count at BioNTech is 5177.

Is BioNTech a funded company?

BioNTech is a funded company, having raised a total of $861M across 11 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2008.

When was the latest funding round of BioNTech?

BioNTech's latest funding was a $***** Post IPO round on Apr 14, 2022, with participation from 0 investor.

Where does BioNTech rank among its competitors?

BioNTech ranks 27th amongst 3632 active competitors, of which 1239 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of BioNTech?

BioNTech's top competitors include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Among them, Senti Bio secured the most recent funding round in May, 2026.

BioNTech - 2026 Company Profile, Team, Funding & Competitors

BioNTech is a public company based in Mainz (Germany), founded in 2008 by Ozlem Tureci and Christoph Huber. It operates as a Developer of immunotherapeutics for the treatment of cancer and other diseases. BioNTech has raised $861M in funding from investors like Fidelity Investments, MIG Fonds and Redmile Group. The company has 3632 active competitors, including 1239 funded and 864 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and Abcellera Biologics.

Company Details

Developer of immunotherapeutics for the treatment of cancer and other diseases. Its oncology drug pipeline contains several classes of drugs which include mRNA treatments, modified cell therapies, antibodies, and small molecule immunomodulators that have been optimised for distinct modes of action, high precision targeting, potency, and efficacy.

Website: www.biontech.com/us/en/home.html
Social
Email ID: *****@biontech.de
Phone Number: +49 **********

Key Metrics

Founded Year

2008

Location

Mainz, Germany

Stage

Public

Total Funding

$861M in 11 rounds

Latest Funding Round

Post IPO, Apr 14, 2022, $*****

Investors

Fidelity Investments & 29 more

Ranked

27^th among 3632 active competitors

Employee Count

5,177 as on May 31, 2026

Investment & Acquisitions

CureVac & 7 more

Similar Companies

Jazz Pharmaceuticals & 3496 more

Exit Details

Public

View BioNTech's full profile

BioNTech is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BioNTech SE CIN: 1776985 , United States, Active		$1 - $1M (As on Apr 14, 2022)	-	-
Biontech Ag CIN: HRB48720 , Germany, Active	Dec 10, 2008	€10M - €50M (As on Dec 31, 2018)	1941 (As on Dec 31, 2020)
BIONTECH USA HOLDING LLC CIN: 364930904 , United States, Active	Dec 31, 1999	-	1 (As on Dec 31, 2020)	-
BioNTech SE. CIN: HRB48720 , Germany, Active	Feb 14, 1995	-	-

BioNTech got listed on Oct 11, 2019.

Click here to take a look at BioNTech's IPO in detail

BioNTech has raised a total funding of $861M over 11 rounds. Its first funding round was on 2008. BioNTech has 30 institutional investors.

Here is the list of recent funding rounds of BioNTech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 14, 2022	3770325	Post IPO	5960152	7268664	5863265	2090983
Sep 07, 2020	5264669	Post IPO	6460759	3255674	9555810	Bmbf
Jun 28, 2020	4912215	Post IPO	7244072	7031784	3153727	Temasek

Access funding benchmarks and valuations. Sign up today!

View details of BioNTech's funding rounds and investors

The founders of BioNTech are Ozlem Tureci and Christoph Huber.

Here are the details of BioNTech's key team members:

Ozlem Tureci: Co-Founder of BioNTech.
Christoph Huber: Co-Founder & Managing Director of BioNTech and founder of 2 other companies, Ganymed Pharmaceuticals and BioNTech.
Contact Info: 1 email address

View details of BioNTech's Founder profiles and Board Members

BioNTech's employee count trend

BioNTech has 5,177 employees as of May 26. Here is BioNTech's employee count trend over the years:

Uncover BioNTech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioNTech include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of BioNTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Omnes Capital, Life Sciences Partners & 20 others	74/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
27th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Janus Henderson Investors, EIP & 28 others	69/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BioNTech's competitors? Click here to see the top ones

BioNTech has made 3 investments in companies including Autolus and Crescendo. BioNTech has also acquired 5 companies including CureVac and Biotheus.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jun 12, 2025	Acquisition	CureVac	2000	Tubingen (Germany)
Nov 13, 2024	Acquisition	Biotheus	2018	Zhuhai (China)
Feb 08, 2024	Investments	Autolus	2015	London (United Kingdom)